SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+25.2%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$697M
AUM Growth
+$697M
(-5.3%)
Cap. Flow
-$125M
Cap. Flow
% of AUM
-17.88%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
97
New
21
Increased
21
Reduced
26
Closed
24
Top Buys
| 1 |
Vericel Corp
VCEL
|
$14.1M |
| 2 |
Celcuity
CELC
|
$10.7M |
| 3 |
HCA Healthcare
HCA
|
$8.29M |
| 4 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$7.81M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$7.65M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$29.6M |
| 2 |
Illumina
ILMN
|
$25.7M |
| 3 |
CVS Health
CVS
|
$17.8M |
| 4 |
Envista
NVST
|
$15.7M |
| 5 |
Eli Lilly
LLY
|
$15.3M |
Sector Composition
| 1 | Healthcare | 97.09% |
| 2 | Consumer Staples | 1.8% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Establishment Labs
ESTA
$1.11B
| $2.62M | 0.38% |
39,920
-22,700
| -36% | -$1.49M |
|
52
Protagonist Therapeutics
PTGX
$3.62B
| $2.57M | 0.37% |
+236,000
| New | +$2.57M |
|
53
10x Genomics
TXG
$1.66B
| $2.55M | 0.37% |
+70,000
| New | +$2.55M |
|
54
Intuitive Surgical
ISRG
$158B
| $2.55M | 0.37% |
9,600
-25,200
| -72% | -$6.69M |
|
55
Ventyx Biosciences
VTYX
$184M
| $2.26M | 0.32% |
+69,000
| New | +$2.26M |
|
56
Neogen
NEOG
$1.24B
| $2.19M | 0.31% |
+143,500
| New | +$2.19M |
|
|
PRDS
57
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $2.11M | 0.3% |
+1,250,000
| New | +$2.11M |
|
58
Penumbra
PEN
$10.5B
| $2.07M | 0.3% |
+9,300
| New | +$2.07M |
|
|
KDNY
59
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $2.04M | 0.29% |
78,000
| – | – |
|
60
Amylyx Pharmaceuticals
AMLX
$877M
| $1.87M | 0.27% |
50,636
-378,700
| -88% | -$14M |
|
61
Lyra Therapeutics
LYRA
$11.8M
| $1.86M | 0.27% |
592,417
| – | – |
|
62
FibroGen
FGEN
$48.4M
| $1.82M | 0.26% |
113,463
-120,563
| -52% | -$1.93M |
|
63
Xenon Pharmaceuticals
XENE
$2.99B
| $1.5M | 0.22% |
38,000
-58,800
| -61% | -$2.32M |
|
|
PVLA
64
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $1.04M | 0.15% |
1,000,000
-3,134,868
| -76% | -$3.26M |
|
65
CRISPR Therapeutics
CRSP
$4.82B
| $894K | 0.13% |
22,000
| – | – |
|
|
CUTR
66
DELISTED
Cutera, Inc.
CUTR
| $884K | 0.13% |
20,000
-235,792
| -92% | -$10.4M |
|
67
Xilio Therapeutics
XLO
$37.5M
| $610K | 0.09% |
226,941
-226,719
| -50% | -$610K |
|
68
Pulmonx
LUNG
$67.6M
| $599K | 0.09% |
+71,000
| New | +$599K |
|
69
AnaptysBio
ANAB
$630M
| $456K | 0.07% |
14,727
-49,300
| -77% | -$1.53M |
|
70
Y-mAbs Therapeutics
YMAB
$390M
| $425K | 0.06% |
87,182
| – | – |
|
71
OrthoPediatrics
KIDS
$524M
| $297K | 0.04% |
+7,471
| New | +$297K |
|
72
PepGen
PEPG
$39M
| $134K | 0.02% |
10,000
-120,000
| -92% | -$1.6M |
|
|
APEN
73
DELISTED
Apollo Endosurgery, Inc.
APEN
| – | – |
-1,137,105
| Closed | -$6.27M |
|
|
DALS
74
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| – | – |
-50,000
| Closed | -$487K |
|
75
Novo Nordisk
NVO
$252B
| – | – |
-14,100
| Closed | -$1.41M |
|